NASDAQ:CRBU Caribou Biosciences Q2 2025 Earnings Report $1.93 -0.20 (-9.39%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$1.96 +0.04 (+1.81%) As of 09/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Caribou Biosciences EPS ResultsActual EPS-$0.35Consensus EPS -$0.40Beat/MissBeat by +$0.05One Year Ago EPSN/ACaribou Biosciences Revenue ResultsActual Revenue$2.67 millionExpected Revenue$1.64 millionBeat/MissBeat by +$1.02 millionYoY Revenue GrowthN/ACaribou Biosciences Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time7:00AM ETUpcoming EarningsCaribou Biosciences' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Caribou Biosciences Earnings HeadlinesBrokers Issue Forecasts for CRBU FY2026 Earnings1 hour ago | americanbankingnews.comCiti Sticks to Its Buy Rating for Caribou Biosciences (CRBU)September 19, 2025 | theglobeandmail.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. | Banyan Hill Publishing (Ad)Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School ConferenceAugust 25, 2025 | globenewswire.comCaribou Biosciences reports Q2 EPS (35c), one estimate (42c)August 12, 2025 | msn.comCaribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comSee More Caribou Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email. Email Address About Caribou BiosciencesCaribou Biosciences (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis. Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies. Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.View Caribou Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO Bulls Upcoming Earnings NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)ASML (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.